B. Fisher et al., ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14, Journal of the National Cancer Institute, 86(7), 1994, pp. 527-537
Background: Tamoxifen is advantageous in treating all stages of breast
cancer. However, studies have suggested that incidence and severity o
f endometrial cancer increase in women treated with tamoxifen. Purpose
: We compared rates of endometrial and other cancers in tamoxifen- and
non-tamoxifen-treated patients and described the pathologic character
istics of the endometrial cancers. Methods: Data were analyzed on 2843
patients with node-negative, estrogen receptor-positive, invasive bre
ast cancer randomly assigned to placebo or tamoxifen (20 mg/d) and on
1220 tamoxifen-treated patients registered in NSABP B-14 subsequent to
randomization. Average time on study is 8 years for randomly assigned
patients and 5 years for registered patients. Results: The incidence
rates of liver, gastrointestinal, urinary tract, and nonuterine genita
l tumors were not increased by tamoxifen treatment. Twenty-five endome
trial cancers were originally reported. one of which was reclassified
after subsequent review. Two cases occurred in the placebo group in pa
tients whose medical status subsequent to random assignment had requir
ed tamoxifen treatment. Twenty-three occurred in the tamoxifen groups.
Twenty-one of the 24 originally reported endometrial cancers were FIG
O stage 1; 18 of 23 gradable cases were of good to moderate histologic
grade. Four tamoxifen-treated women died of uterine cancer. The avera
ge annual hazard rate of endometrial cancer as a first event within th
e first 5 years of follow-up in the randomized, tamoxifen-treated grou
p was 1.2/1000 patient-years; the cumulative hazard rate was 6.3/1000.
Findings for the registered, tamoxifen-treated group were similar. In
cluding all originally reported endometrial cancers, the annual hazard
rate through all follow-up was 0.2/1000 in the placebo group and 1.6/
1000 in the randomized, tamoxifen-treated group; the relative risk of
endometrial cancer for the latter versus the former group was 7.5. Aga
in for the latter group, using population-based rates of endometrial c
ancer from SEER data and information from another NSABP (B-06) trial,
relative risks were 2.2 and 2.3, respectively. The 5-year cumulative h
azard rate for disease-free survival in the randomized tamoxifen group
was 38% less than that in the placebo group. Some data in this paper
were provided by an investigator who submitted fraudulent data to the
NSABP [see the ''News'' section]; therefore, the reader must read the
entire text including Table 10 and the Editor's notes. In brief, data
on 182 of the 2843 randomly assigned patients and 37 of the 1220 regis
tered patients were provided by the investigator in question. After re
view, 24 of the 182 records showed falsification, all involving charac
teristics of patients prior to random assignment. Of the 37 registered
-patient records, 8 showed falsification. Conclusions: Risk of endomet
rial cancer increases following tamoxifen therapy for invasive breast
cancer, however, net benefit greatly outweighs risk. Endometrial cance
rs occurring after tamoxifen therapy do not appear to be of a differen
t type with a worse prognosis than are such tumors in non-tamoxifen-tr
eated patients. Implications: Tamoxifen treatment for breast cancer sh
ould continue. In addition, the relative risk of endometrial cancer ob
served in B-14 tamoxifen-treated patients is consistent with the twofo
ld relative risk used in the initial risk-benefit computation for the
NSABP breast cancer prevention trial.